Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients

Main Article Content

James Del Rosso
JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV

Linda Stein Gold
Henry Ford Health System, Detroit, MI

Leon Kircik
Icahn School of Medicine at Mount Sinai, New York, NY

Andrew Alexis
Mount Sinai, New York, NY

Seemal R. Desai
Innovative Dermatology, Plano, TX; Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX

Vassilis Stakias
VYNE Therapeutics Inc., Bridgewater, NJ

Iain Stuart
VYNE Therapeutics Inc., Bridgewater, NJ

Keywords

Acne Vulgaris, Minocycline, Topical, Efficacy

Abstract

Abstract not available.

References

1. Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2S1):S1-S23.

2. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5)945-973.

3. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019; 80(1):168-177.

4. Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2020;82(4):832-837.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.89

Article Details

How to Cite
[1]
Del Rosso, J. , Gold, L.S., Kircik, L., Alexis, A., Desai, S.R., Stakias, V. and Stuart, I. 2020. Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s89. DOI:https://doi.org/10.25251/skin.4.supp.89.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>